In the APAC region, during the month of JUL the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 2845.
In the APAC region, during the month of JUL the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 2188.
In the APAC region, during the month of JUL the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2178.
In the APAC region, during the month of JUL the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 1822.
In the APAC region, during the month of JUL the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 1149.
In the APAC region, during the month of JUL the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1060.
In the APAC region, during the month of JUL the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 9297.
In the APAC region, during the month of JUL the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 8958.
In the APAC region, during the month of JUL the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 8832.
In the APAC region, during the month of JUL the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6452.
In the APAC region, during the month of JUL the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6780.
In the APAC region, during the month of JUL the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6654.
In the APAC region, during the month of JUL the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1023.
In the APAC region, during the month of JUL the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1039.
In the APAC region, during the month of JUL the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1118.
In the APAC region, during the month of JUL the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 71.
In the APAC region, during the month of JUL the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 70.
In the APAC region, during the month of JUL the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 89.
In the APAC region, during the month of JUL the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 536.
In the APAC region, during the month of JUL the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 160.
In the APAC region, during the month of JUL the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 367.
In the APAC region, during the month of JUL the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 1358.
In the APAC region, during the month of JUL the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 1059.
In the APAC region, during the month of JUL the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 783.
In the APAC region, during the month of JUL the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 107.
In the APAC region, during the month of JUL the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 56.
In the APAC region, during the month of JUL the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 75.
In the APAC region, during the month of JUL the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 131.
In the APAC region, during the month of JUL the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 510.
In the APAC region, during the month of JUL the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 383.
In the APAC region, during the month of JUL the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 255.
In the APAC region, during the month of JUL the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 128.
In the APAC region, during the month of JUL the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 81.
In the APAC region, during the month of JUL the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 30.
In the APAC region, during the month of JUL the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 6767.
In the APAC region, during the month of JUL the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 512.
In the APAC region, during the month of JUL the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3254.
In the APAC region, during the month of JUL the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3139.
In the APAC region, during the month of JUL the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2324.
In the APAC region, during the month of JUL the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2063.
In the APAC region, during the month of JUL the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 1859.
In the APAC region, during the month of JUL the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1525.
In the APAC region, during the month of JUL the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1395.
In the APAC region, during the month of JUL the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1514.
In the APAC region, during the month of JUL the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 455.
In the APAC region, during the month of JUL the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 625.
In the EMEA region, during the month of JUL the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 2945.
In the EMEA region, during the month of JUL the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 2288.
In the EMEA region, during the month of JUL the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2278.
In the EMEA region, during the month of JUL the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 1922.
In the EMEA region, during the month of JUL the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 1249.
In the EMEA region, during the month of JUL the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1160.
In the EMEA region, during the month of JUL the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 9397.
In the EMEA region, during the month of JUL the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 9058.
In the EMEA region, during the month of JUL the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 8932.
In the EMEA region, during the month of JUL the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6552.
In the EMEA region, during the month of JUL the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6880.
In the EMEA region, during the month of JUL the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6754.
In the EMEA region, during the month of JUL the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1123.
In the EMEA region, during the month of JUL the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1139.
In the EMEA region, during the month of JUL the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1218.
In the EMEA region, during the month of JUL the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 171.
In the EMEA region, during the month of JUL the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 170.
In the EMEA region, during the month of JUL the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 189.
In the EMEA region, during the month of JUL the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 636.
In the EMEA region, during the month of JUL the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 260.
In the EMEA region, during the month of JUL the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 467.
In the EMEA region, during the month of JUL the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 1458.
In the EMEA region, during the month of JUL the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 1159.
In the EMEA region, during the month of JUL the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 883.
In the EMEA region, during the month of JUL the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 207.
In the EMEA region, during the month of JUL the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 156.
In the EMEA region, during the month of JUL the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 175.
In the EMEA region, during the month of JUL the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 231.
In the EMEA region, during the month of JUL the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 610.
In the EMEA region, during the month of JUL the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 483.
In the EMEA region, during the month of JUL the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 355.
In the EMEA region, during the month of JUL the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 228.
In the EMEA region, during the month of JUL the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 181.
In the EMEA region, during the month of JUL the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 130.
In the EMEA region, during the month of JUL the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 6867.
In the EMEA region, during the month of JUL the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 612.
In the EMEA region, during the month of JUL the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3354.
In the EMEA region, during the month of JUL the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3239.
In the EMEA region, during the month of JUL the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2424.
In the EMEA region, during the month of JUL the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2163.
In the EMEA region, during the month of JUL the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 1959.
In the EMEA region, during the month of JUL the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1625.
In the EMEA region, during the month of JUL the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1495.
In the EMEA region, during the month of JUL the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1614.
In the EMEA region, during the month of JUL the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 555.
In the EMEA region, during the month of JUL the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 725.
In the North America region, during the month of JUL the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 3192.
In the North America region, during the month of JUL the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 2535.
In the North America region, during the month of JUL the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2525.
In the North America region, during the month of JUL the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 2169.
In the North America region, during the month of JUL the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 1496.
In the North America region, during the month of JUL the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1407.
In the North America region, during the month of JUL the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 9644.
In the North America region, during the month of JUL the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 9305.
In the North America region, during the month of JUL the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 9179.
In the North America region, during the month of JUL the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6799.
In the North America region, during the month of JUL the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 7127.
In the North America region, during the month of JUL the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 7001.
In the North America region, during the month of JUL the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1370.
In the North America region, during the month of JUL the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1386.
In the North America region, during the month of JUL the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1465.
In the North America region, during the month of JUL the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 418.
In the North America region, during the month of JUL the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 417.
In the North America region, during the month of JUL the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 436.
In the North America region, during the month of JUL the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 883.
In the North America region, during the month of JUL the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 507.
In the North America region, during the month of JUL the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 714.
In the North America region, during the month of JUL the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 1705.
In the North America region, during the month of JUL the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 1406.
In the North America region, during the month of JUL the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 1130.
In the North America region, during the month of JUL the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 454.
In the North America region, during the month of JUL the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 403.
In the North America region, during the month of JUL the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 422.
In the North America region, during the month of JUL the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 478.
In the North America region, during the month of JUL the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 857.
In the North America region, during the month of JUL the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 730.
In the North America region, during the month of JUL the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 602.
In the North America region, during the month of JUL the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 475.
In the North America region, during the month of JUL the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 428.
In the North America region, during the month of JUL the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 377.
In the North America region, during the month of JUL the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 7114.
In the North America region, during the month of JUL the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 859.
In the North America region, during the month of JUL the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3601.
In the North America region, during the month of JUL the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3486.
In the North America region, during the month of JUL the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2671.
In the North America region, during the month of JUL the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2410.
In the North America region, during the month of JUL the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 2206.
In the North America region, during the month of JUL the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1872.
In the North America region, during the month of JUL the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1742.
In the North America region, during the month of JUL the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1861.
In the North America region, during the month of JUL the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 802.
In the North America region, during the month of JUL the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 972.
In the APAC region, during the month of AUG the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 1702.
In the APAC region, during the month of AUG the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 2745.
In the APAC region, during the month of AUG the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2728.
In the APAC region, during the month of AUG the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 641.
In the APAC region, during the month of AUG the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 1587.
In the APAC region, during the month of AUG the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1608.
In the APAC region, during the month of AUG the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 8600.
In the APAC region, during the month of AUG the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 8894.
In the APAC region, during the month of AUG the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 9068.
In the APAC region, during the month of AUG the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6898.
In the APAC region, during the month of AUG the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6149.
In the APAC region, during the month of AUG the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6340.
In the APAC region, during the month of AUG the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1061.
In the APAC region, during the month of AUG the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1158.
In the APAC region, during the month of AUG the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1120.
In the APAC region, during the month of AUG the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 89.
In the APAC region, during the month of AUG the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 69.
In the APAC region, during the month of AUG the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 79.
In the APAC region, during the month of AUG the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 294.
In the APAC region, during the month of AUG the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 524.
In the APAC region, during the month of AUG the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 432.
In the APAC region, during the month of AUG the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 436.
In the APAC region, during the month of AUG the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 1132.
In the APAC region, during the month of AUG the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 1255.
In the APAC region, during the month of AUG the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 236.
In the APAC region, during the month of AUG the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 55.
In the APAC region, during the month of AUG the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 74.
In the APAC region, during the month of AUG the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 126.
In the APAC region, during the month of AUG the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 522.
In the APAC region, during the month of AUG the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 392.
In the APAC region, during the month of AUG the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 261.
In the APAC region, during the month of AUG the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 131.
In the APAC region, during the month of AUG the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 39.
In the APAC region, during the month of AUG the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 86.
In the APAC region, during the month of AUG the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 5678.
In the APAC region, during the month of AUG the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 531.
In the APAC region, during the month of AUG the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3010.
In the APAC region, during the month of AUG the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3113.
In the APAC region, during the month of AUG the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2150.
In the APAC region, during the month of AUG the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2046.
In the APAC region, during the month of AUG the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 1720.
In the APAC region, during the month of AUG the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1512.
In the APAC region, during the month of AUG the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1290.
In the APAC region, during the month of AUG the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1601.
In the APAC region, during the month of AUG the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 430.
In the APAC region, during the month of AUG the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 623.
In the EMEA region, during the month of AUG the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 1802.
In the EMEA region, during the month of AUG the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 2845.
In the EMEA region, during the month of AUG the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2828.
In the EMEA region, during the month of AUG the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 741.
In the EMEA region, during the month of AUG the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 1687.
In the EMEA region, during the month of AUG the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1708.
In the EMEA region, during the month of AUG the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 8700.
In the EMEA region, during the month of AUG the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 8994.
In the EMEA region, during the month of AUG the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 9168.
In the EMEA region, during the month of AUG the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6998.
In the EMEA region, during the month of AUG the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6249.
In the EMEA region, during the month of AUG the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6440.
In the EMEA region, during the month of AUG the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1161.
In the EMEA region, during the month of AUG the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1258.
In the EMEA region, during the month of AUG the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1220.
In the EMEA region, during the month of AUG the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 189.
In the EMEA region, during the month of AUG the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 169.
In the EMEA region, during the month of AUG the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 179.
In the EMEA region, during the month of AUG the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 394.
In the EMEA region, during the month of AUG the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 624.
In the EMEA region, during the month of AUG the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 532.
In the EMEA region, during the month of AUG the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 536.
In the EMEA region, during the month of AUG the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 1232.
In the EMEA region, during the month of AUG the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 1355.
In the EMEA region, during the month of AUG the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 336.
In the EMEA region, during the month of AUG the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 155.
In the EMEA region, during the month of AUG the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 174.
In the EMEA region, during the month of AUG the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 226.
In the EMEA region, during the month of AUG the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 622.
In the EMEA region, during the month of AUG the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 492.
In the EMEA region, during the month of AUG the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 361.
In the EMEA region, during the month of AUG the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 231.
In the EMEA region, during the month of AUG the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 139.
In the EMEA region, during the month of AUG the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 186.
In the EMEA region, during the month of AUG the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 5778.
In the EMEA region, during the month of AUG the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 631.
In the EMEA region, during the month of AUG the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3110.
In the EMEA region, during the month of AUG the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3213.
In the EMEA region, during the month of AUG the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2250.
In the EMEA region, during the month of AUG the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2146.
In the EMEA region, during the month of AUG the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 1820.
In the EMEA region, during the month of AUG the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1612.
In the EMEA region, during the month of AUG the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1390.
In the EMEA region, during the month of AUG the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1701.
In the EMEA region, during the month of AUG the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 530.
In the EMEA region, during the month of AUG the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 723.
In the North America region, during the month of AUG the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 2049.
In the North America region, during the month of AUG the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 3092.
In the North America region, during the month of AUG the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 3075.
In the North America region, during the month of AUG the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 988.
In the North America region, during the month of AUG the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 1934.
In the North America region, during the month of AUG the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1955.
In the North America region, during the month of AUG the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 8947.
In the North America region, during the month of AUG the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 9241.
In the North America region, during the month of AUG the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 9415.
In the North America region, during the month of AUG the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 7245.
In the North America region, during the month of AUG the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6496.
In the North America region, during the month of AUG the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6687.
In the North America region, during the month of AUG the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1408.
In the North America region, during the month of AUG the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1505.
In the North America region, during the month of AUG the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1467.
In the North America region, during the month of AUG the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 436.
In the North America region, during the month of AUG the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 416.
In the North America region, during the month of AUG the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 426.
In the North America region, during the month of AUG the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 641.
In the North America region, during the month of AUG the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 871.
In the North America region, during the month of AUG the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 779.
In the North America region, during the month of AUG the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 783.
In the North America region, during the month of AUG the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 1479.
In the North America region, during the month of AUG the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 1602.
In the North America region, during the month of AUG the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 583.
In the North America region, during the month of AUG the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 402.
In the North America region, during the month of AUG the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 421.
In the North America region, during the month of AUG the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 473.
In the North America region, during the month of AUG the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 869.
In the North America region, during the month of AUG the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 739.
In the North America region, during the month of AUG the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 608.
In the North America region, during the month of AUG the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 478.
In the North America region, during the month of AUG the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 386.
In the North America region, during the month of AUG the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 433.
In the North America region, during the month of AUG the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 6025.
In the North America region, during the month of AUG the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 878.
In the North America region, during the month of AUG the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3357.
In the North America region, during the month of AUG the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3460.
In the North America region, during the month of AUG the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2497.
In the North America region, during the month of AUG the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2393.
In the North America region, during the month of AUG the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 2067.
In the North America region, during the month of AUG the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1859.
In the North America region, during the month of AUG the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1637.
In the North America region, during the month of AUG the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1948.
In the North America region, during the month of AUG the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 777.
In the North America region, during the month of AUG the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 970.
In the APAC region, during the month of SEP the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 3323.
In the APAC region, during the month of SEP the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 3224.
In the APAC region, during the month of SEP the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2387.
In the APAC region, during the month of SEP the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 2153.
In the APAC region, during the month of SEP the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 2172.
In the APAC region, during the month of SEP the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1384.
In the APAC region, during the month of SEP the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 9429.
In the APAC region, during the month of SEP the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 9382.
In the APAC region, during the month of SEP the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 8712.
In the APAC region, during the month of SEP the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6106.
In the APAC region, during the month of SEP the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6158.
In the APAC region, during the month of SEP the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6325.
In the APAC region, during the month of SEP the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1170.
In the APAC region, during the month of SEP the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1052.
In the APAC region, during the month of SEP the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1003.
In the APAC region, during the month of SEP the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 50.
In the APAC region, during the month of SEP the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 73.
In the APAC region, during the month of SEP the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 61.
In the APAC region, during the month of SEP the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 348.
In the APAC region, during the month of SEP the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 232.
In the APAC region, during the month of SEP the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 90.
In the APAC region, during the month of SEP the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 1855.
In the APAC region, during the month of SEP the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 2013.
In the APAC region, during the month of SEP the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 1356.
In the APAC region, during the month of SEP the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of -106.
In the APAC region, during the month of SEP the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 54.
In the APAC region, during the month of SEP the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 76.
In the APAC region, during the month of SEP the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 135.
In the APAC region, during the month of SEP the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 540.
In the APAC region, during the month of SEP the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 405.
In the APAC region, during the month of SEP the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 270.
In the APAC region, during the month of SEP the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 135.
In the APAC region, during the month of SEP the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 94.
In the APAC region, during the month of SEP the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 33.
In the APAC region, during the month of SEP the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 6789.
In the APAC region, during the month of SEP the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 585.
In the APAC region, during the month of SEP the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3300.
In the APAC region, during the month of SEP the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3284.
In the APAC region, during the month of SEP the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2357.
In the APAC region, during the month of SEP the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2158.
In the APAC region, during the month of SEP the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 1886.
In the APAC region, during the month of SEP the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1595.
In the APAC region, during the month of SEP the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1414.
In the APAC region, during the month of SEP the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1689.
In the APAC region, during the month of SEP the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 471.
In the APAC region, during the month of SEP the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 557.
In the EMEA region, during the month of SEP the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 3423.
In the EMEA region, during the month of SEP the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 3324.
In the EMEA region, during the month of SEP the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2487.
In the EMEA region, during the month of SEP the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 2253.
In the EMEA region, during the month of SEP the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 2272.
In the EMEA region, during the month of SEP the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1484.
In the EMEA region, during the month of SEP the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 9529.
In the EMEA region, during the month of SEP the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 9482.
In the EMEA region, during the month of SEP the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 8812.
In the EMEA region, during the month of SEP the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6206.
In the EMEA region, during the month of SEP the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6258.
In the EMEA region, during the month of SEP the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6425.
In the EMEA region, during the month of SEP the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1270.
In the EMEA region, during the month of SEP the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1152.
In the EMEA region, during the month of SEP the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1103.
In the EMEA region, during the month of SEP the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 150.
In the EMEA region, during the month of SEP the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 173.
In the EMEA region, during the month of SEP the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 161.
In the EMEA region, during the month of SEP the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 448.
In the EMEA region, during the month of SEP the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 332.
In the EMEA region, during the month of SEP the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 190.
In the EMEA region, during the month of SEP the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 1955.
In the EMEA region, during the month of SEP the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 2113.
In the EMEA region, during the month of SEP the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 1456.
In the EMEA region, during the month of SEP the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of -6.
In the EMEA region, during the month of SEP the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 154.
In the EMEA region, during the month of SEP the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 176.
In the EMEA region, during the month of SEP the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 235.
In the EMEA region, during the month of SEP the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 640.
In the EMEA region, during the month of SEP the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 505.
In the EMEA region, during the month of SEP the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 370.
In the EMEA region, during the month of SEP the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 235.
In the EMEA region, during the month of SEP the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 194.
In the EMEA region, during the month of SEP the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 133.
In the EMEA region, during the month of SEP the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 6889.
In the EMEA region, during the month of SEP the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 685.
In the EMEA region, during the month of SEP the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3400.
In the EMEA region, during the month of SEP the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3384.
In the EMEA region, during the month of SEP the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2457.
In the EMEA region, during the month of SEP the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2258.
In the EMEA region, during the month of SEP the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 1986.
In the EMEA region, during the month of SEP the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1695.
In the EMEA region, during the month of SEP the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1514.
In the EMEA region, during the month of SEP the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1789.
In the EMEA region, during the month of SEP the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 571.
In the EMEA region, during the month of SEP the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 657.
In the North America region, during the month of SEP the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 3670.
In the North America region, during the month of SEP the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 3571.
In the North America region, during the month of SEP the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2734.
In the North America region, during the month of SEP the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 2500.
In the North America region, during the month of SEP the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 2519.
In the North America region, during the month of SEP the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1731.
In the North America region, during the month of SEP the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 9776.
In the North America region, during the month of SEP the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 9729.
In the North America region, during the month of SEP the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 9059.
In the North America region, during the month of SEP the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6453.
In the North America region, during the month of SEP the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6505.
In the North America region, during the month of SEP the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6672.
In the North America region, during the month of SEP the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1517.
In the North America region, during the month of SEP the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1399.
In the North America region, during the month of SEP the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1350.
In the North America region, during the month of SEP the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 397.
In the North America region, during the month of SEP the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 420.
In the North America region, during the month of SEP the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 408.
In the North America region, during the month of SEP the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 695.
In the North America region, during the month of SEP the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 579.
In the North America region, during the month of SEP the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 437.
In the North America region, during the month of SEP the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 2202.
In the North America region, during the month of SEP the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 2360.
In the North America region, during the month of SEP the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 1703.
In the North America region, during the month of SEP the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 241.
In the North America region, during the month of SEP the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 401.
In the North America region, during the month of SEP the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 423.
In the North America region, during the month of SEP the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 482.
In the North America region, during the month of SEP the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 887.
In the North America region, during the month of SEP the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 752.
In the North America region, during the month of SEP the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 617.
In the North America region, during the month of SEP the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 482.
In the North America region, during the month of SEP the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 441.
In the North America region, during the month of SEP the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 380.
In the North America region, during the month of SEP the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 7136.
In the North America region, during the month of SEP the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 932.
In the North America region, during the month of SEP the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3647.
In the North America region, during the month of SEP the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3631.
In the North America region, during the month of SEP the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2704.
In the North America region, during the month of SEP the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2505.
In the North America region, during the month of SEP the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 2233.
In the North America region, during the month of SEP the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1942.
In the North America region, during the month of SEP the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1761.
In the North America region, during the month of SEP the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 2036.
In the North America region, during the month of SEP the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 818.
In the North America region, during the month of SEP the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 904.
In the APAC region, during the month of OCT the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 1822.
In the APAC region, during the month of OCT the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 2651.
In the APAC region, during the month of OCT the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2230.
In the APAC region, during the month of OCT the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 641.
In the APAC region, during the month of OCT the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 1494.
In the APAC region, during the month of OCT the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1182.
In the APAC region, during the month of OCT the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 8200.
In the APAC region, during the month of OCT the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 9163.
In the APAC region, during the month of OCT the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 8910.
In the APAC region, during the month of OCT the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6378.
In the APAC region, during the month of OCT the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6512.
In the APAC region, during the month of OCT the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6680.
In the APAC region, during the month of OCT the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1181.
In the APAC region, during the month of OCT the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1157.
In the APAC region, during the month of OCT the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1048.
In the APAC region, during the month of OCT the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 61.
In the APAC region, during the month of OCT the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 76.
In the APAC region, during the month of OCT the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 55.
In the APAC region, during the month of OCT the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 416.
In the APAC region, during the month of OCT the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 471.
In the APAC region, during the month of OCT the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 509.
In the APAC region, during the month of OCT the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 286.
In the APAC region, during the month of OCT the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 1100.
In the APAC region, during the month of OCT the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 728.
In the APAC region, during the month of OCT the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 179.
In the APAC region, during the month of OCT the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 54.
In the APAC region, during the month of OCT the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 75.
In the APAC region, during the month of OCT the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 132.
In the APAC region, during the month of OCT the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 510.
In the APAC region, during the month of OCT the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 383.
In the APAC region, during the month of OCT the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 255.
In the APAC region, during the month of OCT the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 128.
In the APAC region, during the month of OCT the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 53.
In the APAC region, during the month of OCT the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 79.
In the APAC region, during the month of OCT the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 9876.
In the APAC region, during the month of OCT the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 591.
In the APAC region, during the month of OCT the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 2870.
In the APAC region, during the month of OCT the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3207.
In the APAC region, during the month of OCT the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2050.
In the APAC region, during the month of OCT the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2107.
In the APAC region, during the month of OCT the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 1540.
In the APAC region, during the month of OCT the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1558.
In the APAC region, during the month of OCT the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1230.
In the APAC region, during the month of OCT the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1649.
In the APAC region, during the month of OCT the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 410.
In the APAC region, during the month of OCT the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 641.
In the EMEA region, during the month of OCT the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 1922.
In the EMEA region, during the month of OCT the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 2751.
In the EMEA region, during the month of OCT the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2330.
In the EMEA region, during the month of OCT the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 741.
In the EMEA region, during the month of OCT the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 1594.
In the EMEA region, during the month of OCT the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1282.
In the EMEA region, during the month of OCT the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 8300.
In the EMEA region, during the month of OCT the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 9263.
In the EMEA region, during the month of OCT the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 9010.
In the EMEA region, during the month of OCT the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6478.
In the EMEA region, during the month of OCT the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6612.
In the EMEA region, during the month of OCT the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6780.
In the EMEA region, during the month of OCT the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1281.
In the EMEA region, during the month of OCT the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1257.
In the EMEA region, during the month of OCT the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1148.
In the EMEA region, during the month of OCT the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 161.
In the EMEA region, during the month of OCT the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 176.
In the EMEA region, during the month of OCT the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 155.
In the EMEA region, during the month of OCT the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 516.
In the EMEA region, during the month of OCT the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 571.
In the EMEA region, during the month of OCT the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 609.
In the EMEA region, during the month of OCT the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 386.
In the EMEA region, during the month of OCT the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 1200.
In the EMEA region, during the month of OCT the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 828.
In the EMEA region, during the month of OCT the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 279.
In the EMEA region, during the month of OCT the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 154.
In the EMEA region, during the month of OCT the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 175.
In the EMEA region, during the month of OCT the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 232.
In the EMEA region, during the month of OCT the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 610.
In the EMEA region, during the month of OCT the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 483.
In the EMEA region, during the month of OCT the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 355.
In the EMEA region, during the month of OCT the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 228.
In the EMEA region, during the month of OCT the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 153.
In the EMEA region, during the month of OCT the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 179.
In the EMEA region, during the month of OCT the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 9976.
In the EMEA region, during the month of OCT the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 691.
In the EMEA region, during the month of OCT the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 2970.
In the EMEA region, during the month of OCT the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3307.
In the EMEA region, during the month of OCT the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2150.
In the EMEA region, during the month of OCT the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2207.
In the EMEA region, during the month of OCT the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 1640.
In the EMEA region, during the month of OCT the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1658.
In the EMEA region, during the month of OCT the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1330.
In the EMEA region, during the month of OCT the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1749.
In the EMEA region, during the month of OCT the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 510.
In the EMEA region, during the month of OCT the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 741.
In the North America region, during the month of OCT the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 2169.
In the North America region, during the month of OCT the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 2998.
In the North America region, during the month of OCT the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2577.
In the North America region, during the month of OCT the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 988.
In the North America region, during the month of OCT the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 1841.
In the North America region, during the month of OCT the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1529.
In the North America region, during the month of OCT the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 8547.
In the North America region, during the month of OCT the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 9510.
In the North America region, during the month of OCT the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 9257.
In the North America region, during the month of OCT the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6725.
In the North America region, during the month of OCT the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6859.
In the North America region, during the month of OCT the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 7027.
In the North America region, during the month of OCT the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1528.
In the North America region, during the month of OCT the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1504.
In the North America region, during the month of OCT the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1395.
In the North America region, during the month of OCT the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 408.
In the North America region, during the month of OCT the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 423.
In the North America region, during the month of OCT the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 402.
In the North America region, during the month of OCT the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 763.
In the North America region, during the month of OCT the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 818.
In the North America region, during the month of OCT the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 856.
In the North America region, during the month of OCT the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 633.
In the North America region, during the month of OCT the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 1447.
In the North America region, during the month of OCT the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 1075.
In the North America region, during the month of OCT the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 526.
In the North America region, during the month of OCT the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 401.
In the North America region, during the month of OCT the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 422.
In the North America region, during the month of OCT the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 479.
In the North America region, during the month of OCT the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 857.
In the North America region, during the month of OCT the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 730.
In the North America region, during the month of OCT the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 602.
In the North America region, during the month of OCT the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 475.
In the North America region, during the month of OCT the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 400.
In the North America region, during the month of OCT the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 426.
In the North America region, during the month of OCT the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 10223.
In the North America region, during the month of OCT the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 938.
In the North America region, during the month of OCT the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3217.
In the North America region, during the month of OCT the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3554.
In the North America region, during the month of OCT the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2397.
In the North America region, during the month of OCT the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2454.
In the North America region, during the month of OCT the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 1887.
In the North America region, during the month of OCT the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1905.
In the North America region, during the month of OCT the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1577.
In the North America region, during the month of OCT the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1996.
In the North America region, during the month of OCT the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 757.
In the North America region, during the month of OCT the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 988.
In the APAC region, during the month of NOV the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 2300.
In the APAC region, during the month of NOV the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 1915.
In the APAC region, during the month of NOV the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 3339.
In the APAC region, during the month of NOV the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 1134.
In the APAC region, during the month of NOV the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 892.
In the APAC region, during the month of NOV the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 2316.
In the APAC region, during the month of NOV the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 9047.
In the APAC region, during the month of NOV the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 8811.
In the APAC region, during the month of NOV the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 9404.
In the APAC region, during the month of NOV the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6747.
In the APAC region, during the month of NOV the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6896.
In the APAC region, during the month of NOV the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6065.
In the APAC region, during the month of NOV the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1166.
In the APAC region, during the month of NOV the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1023.
In the APAC region, during the month of NOV the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1023.
In the APAC region, during the month of NOV the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 66.
In the APAC region, during the month of NOV the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 88.
In the APAC region, during the month of NOV the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 55.
In the APAC region, during the month of NOV the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 337.
In the APAC region, during the month of NOV the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 281.
In the APAC region, during the month of NOV the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 376.
In the APAC region, during the month of NOV the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 863.
In the APAC region, during the month of NOV the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 700.
In the APAC region, during the month of NOV the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 1995.
In the APAC region, during the month of NOV the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 235.
In the APAC region, during the month of NOV the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 54.
In the APAC region, during the month of NOV the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 78.
In the APAC region, during the month of NOV the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 127.
In the APAC region, during the month of NOV the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 540.
In the APAC region, during the month of NOV the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 405.
In the APAC region, during the month of NOV the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 270.
In the APAC region, during the month of NOV the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 135.
In the APAC region, during the month of NOV the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 99.
In the APAC region, during the month of NOV the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 33.
In the APAC region, during the month of NOV the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 9090.
In the APAC region, during the month of NOV the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 583.
In the APAC region, during the month of NOV the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3166.
In the APAC region, during the month of NOV the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3084.
In the APAC region, during the month of NOV the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2262.
In the APAC region, during the month of NOV the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2027.
In the APAC region, during the month of NOV the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 1809.
In the APAC region, during the month of NOV the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1495.
In the APAC region, during the month of NOV the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1357.
In the APAC region, during the month of NOV the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1586.
In the APAC region, during the month of NOV the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 432.
In the APAC region, during the month of NOV the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 617.
In the EMEA region, during the month of NOV the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 2400.
In the EMEA region, during the month of NOV the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 2015.
In the EMEA region, during the month of NOV the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 3439.
In the EMEA region, during the month of NOV the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 1234.
In the EMEA region, during the month of NOV the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 992.
In the EMEA region, during the month of NOV the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 2416.
In the EMEA region, during the month of NOV the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 9147.
In the EMEA region, during the month of NOV the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 8911.
In the EMEA region, during the month of NOV the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 9504.
In the EMEA region, during the month of NOV the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6847.
In the EMEA region, during the month of NOV the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6996.
In the EMEA region, during the month of NOV the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6165.
In the EMEA region, during the month of NOV the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1266.
In the EMEA region, during the month of NOV the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1123.
In the EMEA region, during the month of NOV the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1123.
In the EMEA region, during the month of NOV the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 166.
In the EMEA region, during the month of NOV the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 188.
In the EMEA region, during the month of NOV the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 155.
In the EMEA region, during the month of NOV the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 437.
In the EMEA region, during the month of NOV the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 381.
In the EMEA region, during the month of NOV the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 476.
In the EMEA region, during the month of NOV the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 963.
In the EMEA region, during the month of NOV the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 800.
In the EMEA region, during the month of NOV the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 2095.
In the EMEA region, during the month of NOV the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 335.
In the EMEA region, during the month of NOV the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 154.
In the EMEA region, during the month of NOV the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 178.
In the EMEA region, during the month of NOV the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 227.
In the EMEA region, during the month of NOV the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 640.
In the EMEA region, during the month of NOV the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 505.
In the EMEA region, during the month of NOV the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 370.
In the EMEA region, during the month of NOV the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 235.
In the EMEA region, during the month of NOV the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 199.
In the EMEA region, during the month of NOV the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 133.
In the EMEA region, during the month of NOV the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 9190.
In the EMEA region, during the month of NOV the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 683.
In the EMEA region, during the month of NOV the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3266.
In the EMEA region, during the month of NOV the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3184.
In the EMEA region, during the month of NOV the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2362.
In the EMEA region, during the month of NOV the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2127.
In the EMEA region, during the month of NOV the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 1909.
In the EMEA region, during the month of NOV the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1595.
In the EMEA region, during the month of NOV the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1457.
In the EMEA region, during the month of NOV the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1686.
In the EMEA region, during the month of NOV the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 532.
In the EMEA region, during the month of NOV the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 717.
In the North America region, during the month of NOV the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 2647.
In the North America region, during the month of NOV the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 2262.
In the North America region, during the month of NOV the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 3686.
In the North America region, during the month of NOV the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 1481.
In the North America region, during the month of NOV the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 1239.
In the North America region, during the month of NOV the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 2663.
In the North America region, during the month of NOV the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 9394.
In the North America region, during the month of NOV the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 9158.
In the North America region, during the month of NOV the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 9751.
In the North America region, during the month of NOV the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 7094.
In the North America region, during the month of NOV the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 7243.
In the North America region, during the month of NOV the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6412.
In the North America region, during the month of NOV the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1513.
In the North America region, during the month of NOV the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1370.
In the North America region, during the month of NOV the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1370.
In the North America region, during the month of NOV the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 413.
In the North America region, during the month of NOV the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 435.
In the North America region, during the month of NOV the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 402.
In the North America region, during the month of NOV the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 684.
In the North America region, during the month of NOV the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 628.
In the North America region, during the month of NOV the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 723.
In the North America region, during the month of NOV the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 1210.
In the North America region, during the month of NOV the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 1047.
In the North America region, during the month of NOV the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 2342.
In the North America region, during the month of NOV the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 582.
In the North America region, during the month of NOV the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 401.
In the North America region, during the month of NOV the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 425.
In the North America region, during the month of NOV the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 474.
In the North America region, during the month of NOV the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 887.
In the North America region, during the month of NOV the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 752.
In the North America region, during the month of NOV the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 617.
In the North America region, during the month of NOV the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 482.
In the North America region, during the month of NOV the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 446.
In the North America region, during the month of NOV the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 380.
In the North America region, during the month of NOV the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 9437.
In the North America region, during the month of NOV the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 930.
In the North America region, during the month of NOV the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3513.
In the North America region, during the month of NOV the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3431.
In the North America region, during the month of NOV the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2609.
In the North America region, during the month of NOV the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2374.
In the North America region, during the month of NOV the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 2156.
In the North America region, during the month of NOV the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1842.
In the North America region, during the month of NOV the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1704.
In the North America region, during the month of NOV the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1933.
In the North America region, during the month of NOV the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 779.
In the North America region, during the month of NOV the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 964.
In the APAC region, during the month of DEC the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 2847.
In the APAC region, during the month of DEC the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 1979.
In the APAC region, during the month of DEC the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2322.
In the APAC region, during the month of DEC the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 1769.
In the APAC region, during the month of DEC the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 973.
In the APAC region, during the month of DEC the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1308.
In the APAC region, during the month of DEC the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 8958.
In the APAC region, during the month of DEC the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 8662.
In the APAC region, during the month of DEC the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 8587.
In the APAC region, during the month of DEC the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6121.
In the APAC region, during the month of DEC the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6683.
In the APAC region, during the month of DEC the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6265.
In the APAC region, during the month of DEC the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1078.
In the APAC region, during the month of DEC the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1006.
In the APAC region, during the month of DEC the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1014.
In the APAC region, during the month of DEC the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 88.
In the APAC region, during the month of DEC the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 53.
In the APAC region, during the month of DEC the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 80.
In the APAC region, during the month of DEC the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 345.
In the APAC region, during the month of DEC the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 226.
In the APAC region, during the month of DEC the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 338.
In the APAC region, during the month of DEC the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 1512.
In the APAC region, during the month of DEC the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 800.
In the APAC region, during the month of DEC the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 1051.
In the APAC region, during the month of DEC the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 205.
In the APAC region, during the month of DEC the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 54.
In the APAC region, during the month of DEC the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 77.
In the APAC region, during the month of DEC the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 130.
In the APAC region, during the month of DEC the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 510.
In the APAC region, during the month of DEC the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 383.
In the APAC region, during the month of DEC the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 255.
In the APAC region, during the month of DEC the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 128.
In the APAC region, during the month of DEC the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 29.
In the APAC region, during the month of DEC the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 43.
In the APAC region, during the month of DEC the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 8765.
In the APAC region, during the month of DEC the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 539.
In the APAC region, during the month of DEC the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3193.
In the APAC region, during the month of DEC the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3032.
In the APAC region, during the month of DEC the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2242.
In the APAC region, during the month of DEC the CRG - Clinical group operating under the Development division, achieved a Target Sales of 1992.
In the APAC region, during the month of DEC the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 1794.
In the APAC region, during the month of DEC the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1473.
In the APAC region, during the month of DEC the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1345.
In the APAC region, during the month of DEC the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1599.
In the APAC region, during the month of DEC the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 448.
In the APAC region, during the month of DEC the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 606.
In the EMEA region, during the month of DEC the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 2947.
In the EMEA region, during the month of DEC the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 2079.
In the EMEA region, during the month of DEC the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2422.
In the EMEA region, during the month of DEC the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 1869.
In the EMEA region, during the month of DEC the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 1073.
In the EMEA region, during the month of DEC the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1408.
In the EMEA region, during the month of DEC the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 9058.
In the EMEA region, during the month of DEC the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 8762.
In the EMEA region, during the month of DEC the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 8687.
In the EMEA region, during the month of DEC the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6221.
In the EMEA region, during the month of DEC the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6783.
In the EMEA region, during the month of DEC the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6365.
In the EMEA region, during the month of DEC the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1178.
In the EMEA region, during the month of DEC the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1106.
In the EMEA region, during the month of DEC the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1114.
In the EMEA region, during the month of DEC the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 188.
In the EMEA region, during the month of DEC the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 153.
In the EMEA region, during the month of DEC the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 180.
In the EMEA region, during the month of DEC the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 445.
In the EMEA region, during the month of DEC the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 326.
In the EMEA region, during the month of DEC the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 438.
In the EMEA region, during the month of DEC the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 1612.
In the EMEA region, during the month of DEC the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 900.
In the EMEA region, during the month of DEC the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 1151.
In the EMEA region, during the month of DEC the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 305.
In the EMEA region, during the month of DEC the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 154.
In the EMEA region, during the month of DEC the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 177.
In the EMEA region, during the month of DEC the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 230.
In the EMEA region, during the month of DEC the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 610.
In the EMEA region, during the month of DEC the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 483.
In the EMEA region, during the month of DEC the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 355.
In the EMEA region, during the month of DEC the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 228.
In the EMEA region, during the month of DEC the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 129.
In the EMEA region, during the month of DEC the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 143.
In the EMEA region, during the month of DEC the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 8865.
In the EMEA region, during the month of DEC the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 639.
In the EMEA region, during the month of DEC the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3293.
In the EMEA region, during the month of DEC the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3132.
In the EMEA region, during the month of DEC the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2342.
In the EMEA region, during the month of DEC the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2092.
In the EMEA region, during the month of DEC the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 1894.
In the EMEA region, during the month of DEC the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1573.
In the EMEA region, during the month of DEC the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1445.
In the EMEA region, during the month of DEC the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1699.
In the EMEA region, during the month of DEC the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 548.
In the EMEA region, during the month of DEC the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 706.
In the North America region, during the month of DEC the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 3194.
In the North America region, during the month of DEC the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 2326.
In the North America region, during the month of DEC the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2669.
In the North America region, during the month of DEC the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 2116.
In the North America region, during the month of DEC the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 1320.
In the North America region, during the month of DEC the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1655.
In the North America region, during the month of DEC the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 9305.
In the North America region, during the month of DEC the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 9009.
In the North America region, during the month of DEC the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 8934.
In the North America region, during the month of DEC the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6468.
In the North America region, during the month of DEC the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 7030.
In the North America region, during the month of DEC the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6612.
In the North America region, during the month of DEC the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1425.
In the North America region, during the month of DEC the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1353.
In the North America region, during the month of DEC the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1361.
In the North America region, during the month of DEC the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 435.
In the North America region, during the month of DEC the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 400.
In the North America region, during the month of DEC the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 427.
In the North America region, during the month of DEC the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 692.
In the North America region, during the month of DEC the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 573.
In the North America region, during the month of DEC the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 685.
In the North America region, during the month of DEC the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 1859.
In the North America region, during the month of DEC the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 1147.
In the North America region, during the month of DEC the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 1398.
In the North America region, during the month of DEC the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 552.
In the North America region, during the month of DEC the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 401.
In the North America region, during the month of DEC the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 424.
In the North America region, during the month of DEC the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 477.
In the North America region, during the month of DEC the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 857.
In the North America region, during the month of DEC the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 730.
In the North America region, during the month of DEC the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 602.
In the North America region, during the month of DEC the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 475.
In the North America region, during the month of DEC the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 376.
In the North America region, during the month of DEC the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 390.
In the North America region, during the month of DEC the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 9112.
In the North America region, during the month of DEC the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 886.
In the North America region, during the month of DEC the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3540.
In the North America region, during the month of DEC the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3379.
In the North America region, during the month of DEC the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2589.
In the North America region, during the month of DEC the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2339.
In the North America region, during the month of DEC the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 2141.
In the North America region, during the month of DEC the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1820.
In the North America region, during the month of DEC the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1692.
In the North America region, during the month of DEC the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1946.
In the North America region, during the month of DEC the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 795.
In the North America region, during the month of DEC the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 953.
In the APAC region, during the month of JAN the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 2576.
In the APAC region, during the month of JAN the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 2192.
In the APAC region, during the month of JAN the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2555.
In the APAC region, during the month of JAN the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 1388.
In the APAC region, during the month of JAN the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 1086.
In the APAC region, during the month of JAN the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1448.
In the APAC region, during the month of JAN the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 9178.
In the APAC region, during the month of JAN the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 8705.
In the APAC region, during the month of JAN the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 8637.
In the APAC region, during the month of JAN the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6602.
In the APAC region, during the month of JAN the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6513.
In the APAC region, during the month of JAN the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6082.
In the APAC region, during the month of JAN the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1188.
In the APAC region, during the month of JAN the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1106.
In the APAC region, during the month of JAN the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1107.
In the APAC region, during the month of JAN the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 76.
In the APAC region, during the month of JAN the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 59.
In the APAC region, during the month of JAN the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 85.
In the APAC region, during the month of JAN the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 487.
In the APAC region, during the month of JAN the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 298.
In the APAC region, during the month of JAN the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 376.
In the APAC region, during the month of JAN the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 977.
In the APAC region, during the month of JAN the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 847.
In the APAC region, during the month of JAN the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 1157.
In the APAC region, during the month of JAN the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 239.
In the APAC region, during the month of JAN the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 57.
In the APAC region, during the month of JAN the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 75.
In the APAC region, during the month of JAN the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 135.
In the APAC region, during the month of JAN the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 516.
In the APAC region, during the month of JAN the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 387.
In the APAC region, during the month of JAN the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 258.
In the APAC region, during the month of JAN the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 129.
In the APAC region, during the month of JAN the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 58.
In the APAC region, during the month of JAN the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 68.
In the APAC region, during the month of JAN the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 9087.
In the APAC region, during the month of JAN the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 594.
In the APAC region, during the month of JAN the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3112.
In the APAC region, during the month of JAN the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3047.
In the APAC region, during the month of JAN the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2295.
In the APAC region, during the month of JAN the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2002.
In the APAC region, during the month of JAN the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 1835.
In the APAC region, during the month of JAN the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1480.
In the APAC region, during the month of JAN the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1377.
In the APAC region, during the month of JAN the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1387.
In the APAC region, during the month of JAN the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 459.
In the APAC region, during the month of JAN the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 509.
In the EMEA region, during the month of JAN the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 2676.
In the EMEA region, during the month of JAN the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 2292.
In the EMEA region, during the month of JAN the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2655.
In the EMEA region, during the month of JAN the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 1488.
In the EMEA region, during the month of JAN the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 1186.
In the EMEA region, during the month of JAN the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1548.
In the EMEA region, during the month of JAN the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 9278.
In the EMEA region, during the month of JAN the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 8805.
In the EMEA region, during the month of JAN the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 8737.
In the EMEA region, during the month of JAN the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6702.
In the EMEA region, during the month of JAN the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6613.
In the EMEA region, during the month of JAN the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6182.
In the EMEA region, during the month of JAN the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1288.
In the EMEA region, during the month of JAN the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1206.
In the EMEA region, during the month of JAN the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1207.
In the EMEA region, during the month of JAN the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 176.
In the EMEA region, during the month of JAN the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 159.
In the EMEA region, during the month of JAN the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 185.
In the EMEA region, during the month of JAN the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 587.
In the EMEA region, during the month of JAN the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 398.
In the EMEA region, during the month of JAN the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 476.
In the EMEA region, during the month of JAN the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 1077.
In the EMEA region, during the month of JAN the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 947.
In the EMEA region, during the month of JAN the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 1257.
In the EMEA region, during the month of JAN the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 339.
In the EMEA region, during the month of JAN the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 157.
In the EMEA region, during the month of JAN the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 175.
In the EMEA region, during the month of JAN the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 235.
In the EMEA region, during the month of JAN the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 616.
In the EMEA region, during the month of JAN the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 487.
In the EMEA region, during the month of JAN the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 358.
In the EMEA region, during the month of JAN the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 229.
In the EMEA region, during the month of JAN the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 158.
In the EMEA region, during the month of JAN the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 168.
In the EMEA region, during the month of JAN the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 9187.
In the EMEA region, during the month of JAN the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 694.
In the EMEA region, during the month of JAN the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3212.
In the EMEA region, during the month of JAN the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3147.
In the EMEA region, during the month of JAN the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2395.
In the EMEA region, during the month of JAN the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2102.
In the EMEA region, during the month of JAN the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 1935.
In the EMEA region, during the month of JAN the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1580.
In the EMEA region, during the month of JAN the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1477.
In the EMEA region, during the month of JAN the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1487.
In the EMEA region, during the month of JAN the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 559.
In the EMEA region, during the month of JAN the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 609.
In the North America region, during the month of JAN the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 2923.
In the North America region, during the month of JAN the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 2539.
In the North America region, during the month of JAN the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2902.
In the North America region, during the month of JAN the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 1735.
In the North America region, during the month of JAN the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 1433.
In the North America region, during the month of JAN the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1795.
In the North America region, during the month of JAN the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 9525.
In the North America region, during the month of JAN the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 9052.
In the North America region, during the month of JAN the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 8984.
In the North America region, during the month of JAN the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6949.
In the North America region, during the month of JAN the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6860.
In the North America region, during the month of JAN the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6429.
In the North America region, during the month of JAN the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1535.
In the North America region, during the month of JAN the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1453.
In the North America region, during the month of JAN the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1454.
In the North America region, during the month of JAN the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 423.
In the North America region, during the month of JAN the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 406.
In the North America region, during the month of JAN the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 432.
In the North America region, during the month of JAN the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 834.
In the North America region, during the month of JAN the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 645.
In the North America region, during the month of JAN the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 723.
In the North America region, during the month of JAN the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 1324.
In the North America region, during the month of JAN the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 1194.
In the North America region, during the month of JAN the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 1504.
In the North America region, during the month of JAN the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 586.
In the North America region, during the month of JAN the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 404.
In the North America region, during the month of JAN the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 422.
In the North America region, during the month of JAN the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 482.
In the North America region, during the month of JAN the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 863.
In the North America region, during the month of JAN the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 734.
In the North America region, during the month of JAN the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 605.
In the North America region, during the month of JAN the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 476.
In the North America region, during the month of JAN the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 405.
In the North America region, during the month of JAN the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 415.
In the North America region, during the month of JAN the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 9434.
In the North America region, during the month of JAN the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 941.
In the North America region, during the month of JAN the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3459.
In the North America region, during the month of JAN the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3394.
In the North America region, during the month of JAN the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2642.
In the North America region, during the month of JAN the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2349.
In the North America region, during the month of JAN the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 2182.
In the North America region, during the month of JAN the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1827.
In the North America region, during the month of JAN the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1724.
In the North America region, during the month of JAN the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1734.
In the North America region, during the month of JAN the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 806.
In the North America region, during the month of JAN the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 856.
In the APAC region, during the month of FEB the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 2648.
In the APAC region, during the month of FEB the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 2802.
In the APAC region, during the month of FEB the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 1894.
In the APAC region, during the month of FEB the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 1548.
In the APAC region, during the month of FEB the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 1800.
In the APAC region, during the month of FEB the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 833.
In the APAC region, during the month of FEB the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 8681.
In the APAC region, during the month of FEB the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 9171.
In the APAC region, during the month of FEB the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 8671.
In the APAC region, during the month of FEB the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6033.
In the APAC region, during the month of FEB the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6369.
In the APAC region, during the month of FEB the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6777.
In the APAC region, during the month of FEB the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1100.
In the APAC region, during the month of FEB the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1002.
In the APAC region, during the month of FEB the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1061.
In the APAC region, during the month of FEB the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 74.
In the APAC region, during the month of FEB the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 50.
In the APAC region, during the month of FEB the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 69.
In the APAC region, during the month of FEB the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 313.
In the APAC region, during the month of FEB the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 567.
In the APAC region, during the month of FEB the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 399.
In the APAC region, during the month of FEB the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 1310.
In the APAC region, during the month of FEB the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 1284.
In the APAC region, during the month of FEB the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 504.
In the APAC region, during the month of FEB the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of -254.
In the APAC region, during the month of FEB the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 59.
In the APAC region, during the month of FEB the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 74.
In the APAC region, during the month of FEB the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 125.
In the APAC region, during the month of FEB the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 540.
In the APAC region, during the month of FEB the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 405.
In the APAC region, during the month of FEB the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 270.
In the APAC region, during the month of FEB the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 135.
In the APAC region, during the month of FEB the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 87.
In the APAC region, during the month of FEB the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 84.
In the APAC region, during the month of FEB the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 6543.
In the APAC region, during the month of FEB the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 550.
In the APAC region, during the month of FEB the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3038.
In the APAC region, during the month of FEB the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3210.
In the APAC region, during the month of FEB the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2170.
In the APAC region, during the month of FEB the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2109.
In the APAC region, during the month of FEB the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 1736.
In the APAC region, during the month of FEB the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1559.
In the APAC region, during the month of FEB the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1302.
In the APAC region, during the month of FEB the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1651.
In the APAC region, during the month of FEB the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 434.
In the APAC region, during the month of FEB the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 542.
In the EMEA region, during the month of FEB the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 2748.
In the EMEA region, during the month of FEB the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 2902.
In the EMEA region, during the month of FEB the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 1994.
In the EMEA region, during the month of FEB the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 1648.
In the EMEA region, during the month of FEB the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 1900.
In the EMEA region, during the month of FEB the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 933.
In the EMEA region, during the month of FEB the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 8781.
In the EMEA region, during the month of FEB the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 9271.
In the EMEA region, during the month of FEB the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 8771.
In the EMEA region, during the month of FEB the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6133.
In the EMEA region, during the month of FEB the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6469.
In the EMEA region, during the month of FEB the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6877.
In the EMEA region, during the month of FEB the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1200.
In the EMEA region, during the month of FEB the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1102.
In the EMEA region, during the month of FEB the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1161.
In the EMEA region, during the month of FEB the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 174.
In the EMEA region, during the month of FEB the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 150.
In the EMEA region, during the month of FEB the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 169.
In the EMEA region, during the month of FEB the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 413.
In the EMEA region, during the month of FEB the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 667.
In the EMEA region, during the month of FEB the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 499.
In the EMEA region, during the month of FEB the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 1410.
In the EMEA region, during the month of FEB the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 1384.
In the EMEA region, during the month of FEB the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 604.
In the EMEA region, during the month of FEB the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of -154.
In the EMEA region, during the month of FEB the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 159.
In the EMEA region, during the month of FEB the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 174.
In the EMEA region, during the month of FEB the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 225.
In the EMEA region, during the month of FEB the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 640.
In the EMEA region, during the month of FEB the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 505.
In the EMEA region, during the month of FEB the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 370.
In the EMEA region, during the month of FEB the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 235.
In the EMEA region, during the month of FEB the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 187.
In the EMEA region, during the month of FEB the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 184.
In the EMEA region, during the month of FEB the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 6643.
In the EMEA region, during the month of FEB the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 650.
In the EMEA region, during the month of FEB the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3138.
In the EMEA region, during the month of FEB the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3310.
In the EMEA region, during the month of FEB the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2270.
In the EMEA region, during the month of FEB the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2209.
In the EMEA region, during the month of FEB the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 1836.
In the EMEA region, during the month of FEB the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1659.
In the EMEA region, during the month of FEB the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1402.
In the EMEA region, during the month of FEB the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1751.
In the EMEA region, during the month of FEB the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 534.
In the EMEA region, during the month of FEB the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 642.
In the North America region, during the month of FEB the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 2995.
In the North America region, during the month of FEB the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 3149.
In the North America region, during the month of FEB the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2241.
In the North America region, during the month of FEB the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 1895.
In the North America region, during the month of FEB the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 2147.
In the North America region, during the month of FEB the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1180.
In the North America region, during the month of FEB the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 9028.
In the North America region, during the month of FEB the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 9518.
In the North America region, during the month of FEB the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 9018.
In the North America region, during the month of FEB the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6380.
In the North America region, during the month of FEB the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6716.
In the North America region, during the month of FEB the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 7124.
In the North America region, during the month of FEB the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1447.
In the North America region, during the month of FEB the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1349.
In the North America region, during the month of FEB the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1408.
In the North America region, during the month of FEB the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 421.
In the North America region, during the month of FEB the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 397.
In the North America region, during the month of FEB the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 416.
In the North America region, during the month of FEB the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 660.
In the North America region, during the month of FEB the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 914.
In the North America region, during the month of FEB the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 746.
In the North America region, during the month of FEB the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 1657.
In the North America region, during the month of FEB the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 1631.
In the North America region, during the month of FEB the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 851.
In the North America region, during the month of FEB the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 93.
In the North America region, during the month of FEB the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 406.
In the North America region, during the month of FEB the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 421.
In the North America region, during the month of FEB the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 472.
In the North America region, during the month of FEB the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 887.
In the North America region, during the month of FEB the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 752.
In the North America region, during the month of FEB the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 617.
In the North America region, during the month of FEB the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 482.
In the North America region, during the month of FEB the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 434.
In the North America region, during the month of FEB the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 431.
In the North America region, during the month of FEB the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 6890.
In the North America region, during the month of FEB the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 897.
In the North America region, during the month of FEB the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3385.
In the North America region, during the month of FEB the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3557.
In the North America region, during the month of FEB the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2517.
In the North America region, during the month of FEB the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2456.
In the North America region, during the month of FEB the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 2083.
In the North America region, during the month of FEB the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1906.
In the North America region, during the month of FEB the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1649.
In the North America region, during the month of FEB the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1998.
In the North America region, during the month of FEB the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 781.
In the North America region, during the month of FEB the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 889.
In the APAC region, during the month of MAR the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 2763.
In the APAC region, during the month of MAR the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 1825.
In the APAC region, during the month of MAR the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2164.
In the APAC region, during the month of MAR the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 1685.
In the APAC region, during the month of MAR the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 695.
In the APAC region, during the month of MAR the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 988.
In the APAC region, during the month of MAR the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 9211.
In the APAC region, during the month of MAR the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 8617.
In the APAC region, during the month of MAR the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 9102.
In the APAC region, during the month of MAR the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6448.
In the APAC region, during the month of MAR the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6792.
In the APAC region, during the month of MAR the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6938.
In the APAC region, during the month of MAR the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1078.
In the APAC region, during the month of MAR the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1130.
In the APAC region, during the month of MAR the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1176.
In the APAC region, during the month of MAR the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 76.
In the APAC region, during the month of MAR the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 59.
In the APAC region, during the month of MAR the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 58.
In the APAC region, during the month of MAR the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 221.
In the APAC region, during the month of MAR the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 359.
In the APAC region, during the month of MAR the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 234.
In the APAC region, during the month of MAR the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 1540.
In the APAC region, during the month of MAR the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 395.
In the APAC region, during the month of MAR the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 812.
In the APAC region, during the month of MAR the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 281.
In the APAC region, during the month of MAR the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 58.
In the APAC region, during the month of MAR the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 73.
In the APAC region, during the month of MAR the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 125.
In the APAC region, during the month of MAR the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 510.
In the APAC region, during the month of MAR the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 383.
In the APAC region, during the month of MAR the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 255.
In the APAC region, during the month of MAR the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 128.
In the APAC region, during the month of MAR the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 40.
In the APAC region, during the month of MAR the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 74.
In the APAC region, during the month of MAR the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 7865.
In the APAC region, during the month of MAR the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 539.
In the APAC region, during the month of MAR the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3224.
In the APAC region, during the month of MAR the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3015.
In the APAC region, during the month of MAR the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2303.
In the APAC region, during the month of MAR the CRG - Clinical group operating under the Development division, achieved a Target Sales of 1982.
In the APAC region, during the month of MAR the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 1842.
In the APAC region, during the month of MAR the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1455.
In the APAC region, during the month of MAR the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1382.
In the APAC region, during the month of MAR the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1551.
In the APAC region, during the month of MAR the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 461.
In the APAC region, during the month of MAR the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 503.
In the EMEA region, during the month of MAR the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 2863.
In the EMEA region, during the month of MAR the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 1925.
In the EMEA region, during the month of MAR the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2264.
In the EMEA region, during the month of MAR the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 1785.
In the EMEA region, during the month of MAR the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 795.
In the EMEA region, during the month of MAR the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1088.
In the EMEA region, during the month of MAR the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 9311.
In the EMEA region, during the month of MAR the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 8717.
In the EMEA region, during the month of MAR the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 9202.
In the EMEA region, during the month of MAR the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6548.
In the EMEA region, during the month of MAR the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6892.
In the EMEA region, during the month of MAR the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 7038.
In the EMEA region, during the month of MAR the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1178.
In the EMEA region, during the month of MAR the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1230.
In the EMEA region, during the month of MAR the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1276.
In the EMEA region, during the month of MAR the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 176.
In the EMEA region, during the month of MAR the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 159.
In the EMEA region, during the month of MAR the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 158.
In the EMEA region, during the month of MAR the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 321.
In the EMEA region, during the month of MAR the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 459.
In the EMEA region, during the month of MAR the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 334.
In the EMEA region, during the month of MAR the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 1640.
In the EMEA region, during the month of MAR the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 495.
In the EMEA region, during the month of MAR the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 912.
In the EMEA region, during the month of MAR the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 381.
In the EMEA region, during the month of MAR the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 158.
In the EMEA region, during the month of MAR the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 173.
In the EMEA region, during the month of MAR the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 225.
In the EMEA region, during the month of MAR the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 610.
In the EMEA region, during the month of MAR the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 483.
In the EMEA region, during the month of MAR the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 355.
In the EMEA region, during the month of MAR the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 228.
In the EMEA region, during the month of MAR the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 140.
In the EMEA region, during the month of MAR the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 174.
In the EMEA region, during the month of MAR the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 7965.
In the EMEA region, during the month of MAR the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 639.
In the EMEA region, during the month of MAR the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3324.
In the EMEA region, during the month of MAR the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3115.
In the EMEA region, during the month of MAR the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2403.
In the EMEA region, during the month of MAR the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2082.
In the EMEA region, during the month of MAR the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 1942.
In the EMEA region, during the month of MAR the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1555.
In the EMEA region, during the month of MAR the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1482.
In the EMEA region, during the month of MAR the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1651.
In the EMEA region, during the month of MAR the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 561.
In the EMEA region, during the month of MAR the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 603.
In the North America region, during the month of MAR the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 3110.
In the North America region, during the month of MAR the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 2172.
In the North America region, during the month of MAR the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2511.
In the North America region, during the month of MAR the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 2032.
In the North America region, during the month of MAR the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 1042.
In the North America region, during the month of MAR the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1335.
In the North America region, during the month of MAR the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 9558.
In the North America region, during the month of MAR the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 8964.
In the North America region, during the month of MAR the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 9449.
In the North America region, during the month of MAR the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6795.
In the North America region, during the month of MAR the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 7139.
In the North America region, during the month of MAR the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 7285.
In the North America region, during the month of MAR the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1425.
In the North America region, during the month of MAR the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1477.
In the North America region, during the month of MAR the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1523.
In the North America region, during the month of MAR the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 423.
In the North America region, during the month of MAR the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 406.
In the North America region, during the month of MAR the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 405.
In the North America region, during the month of MAR the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 568.
In the North America region, during the month of MAR the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 706.
In the North America region, during the month of MAR the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 581.
In the North America region, during the month of MAR the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 1887.
In the North America region, during the month of MAR the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 742.
In the North America region, during the month of MAR the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 1159.
In the North America region, during the month of MAR the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 628.
In the North America region, during the month of MAR the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 405.
In the North America region, during the month of MAR the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 420.
In the North America region, during the month of MAR the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 472.
In the North America region, during the month of MAR the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 857.
In the North America region, during the month of MAR the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 730.
In the North America region, during the month of MAR the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 602.
In the North America region, during the month of MAR the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 475.
In the North America region, during the month of MAR the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 387.
In the North America region, during the month of MAR the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 421.
In the North America region, during the month of MAR the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 8212.
In the North America region, during the month of MAR the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 886.
In the North America region, during the month of MAR the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3571.
In the North America region, during the month of MAR the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3362.
In the North America region, during the month of MAR the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2650.
In the North America region, during the month of MAR the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2329.
In the North America region, during the month of MAR the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 2189.
In the North America region, during the month of MAR the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1802.
In the North America region, during the month of MAR the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1729.
In the North America region, during the month of MAR the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1898.
In the North America region, during the month of MAR the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 808.
In the North America region, during the month of MAR the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 850.
In the APAC region, during the month of APR the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 3136.
In the APAC region, during the month of APR the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 2919.
In the APAC region, during the month of APR the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2194.
In the APAC region, during the month of APR the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 1937.
In the APAC region, during the month of APR the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 1745.
In the APAC region, during the month of APR the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 998.
In the APAC region, during the month of APR the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 9409.
In the APAC region, during the month of APR the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 9355.
In the APAC region, during the month of APR the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 8769.
In the APAC region, during the month of APR the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6273.
In the APAC region, during the month of APR the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6436.
In the APAC region, during the month of APR the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6575.
In the APAC region, during the month of APR the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1199.
In the APAC region, during the month of APR the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1174.
In the APAC region, during the month of APR the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1196.
In the APAC region, during the month of APR the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 74.
In the APAC region, during the month of APR the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 57.
In the APAC region, during the month of APR the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 84.
In the APAC region, during the month of APR the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 297.
In the APAC region, during the month of APR the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 410.
In the APAC region, during the month of APR the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 252.
In the APAC region, during the month of APR the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 1714.
In the APAC region, during the month of APR the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 1392.
In the APAC region, during the month of APR the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 830.
In the APAC region, during the month of APR the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 221.
In the APAC region, during the month of APR the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 57.
In the APAC region, during the month of APR the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 71.
In the APAC region, during the month of APR the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 134.
In the APAC region, during the month of APR the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 540.
In the APAC region, during the month of APR the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 405.
In the APAC region, during the month of APR the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 270.
In the APAC region, during the month of APR the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 135.
In the APAC region, during the month of APR the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 110.
In the APAC region, during the month of APR the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 61.
In the APAC region, during the month of APR the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 8976.
In the APAC region, during the month of APR the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 600.
In the APAC region, during the month of APR the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3293.
In the APAC region, during the month of APR the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3274.
In the APAC region, during the month of APR the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2352.
In the APAC region, during the month of APR the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2152.
In the APAC region, during the month of APR the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 1882.
In the APAC region, during the month of APR the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1590.
In the APAC region, during the month of APR the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1411.
In the APAC region, during the month of APR the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1684.
In the APAC region, during the month of APR the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 470.
In the APAC region, during the month of APR the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 633.
In the EMEA region, during the month of APR the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 3236.
In the EMEA region, during the month of APR the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 3019.
In the EMEA region, during the month of APR the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2294.
In the EMEA region, during the month of APR the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 2037.
In the EMEA region, during the month of APR the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 1845.
In the EMEA region, during the month of APR the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1098.
In the EMEA region, during the month of APR the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 9509.
In the EMEA region, during the month of APR the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 9455.
In the EMEA region, during the month of APR the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 8869.
In the EMEA region, during the month of APR the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6373.
In the EMEA region, during the month of APR the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6536.
In the EMEA region, during the month of APR the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6675.
In the EMEA region, during the month of APR the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1299.
In the EMEA region, during the month of APR the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1274.
In the EMEA region, during the month of APR the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1296.
In the EMEA region, during the month of APR the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 174.
In the EMEA region, during the month of APR the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 157.
In the EMEA region, during the month of APR the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 184.
In the EMEA region, during the month of APR the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 397.
In the EMEA region, during the month of APR the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 510.
In the EMEA region, during the month of APR the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 352.
In the EMEA region, during the month of APR the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 1814.
In the EMEA region, during the month of APR the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 1492.
In the EMEA region, during the month of APR the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 930.
In the EMEA region, during the month of APR the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 321.
In the EMEA region, during the month of APR the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 157.
In the EMEA region, during the month of APR the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 171.
In the EMEA region, during the month of APR the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 234.
In the EMEA region, during the month of APR the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 640.
In the EMEA region, during the month of APR the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 505.
In the EMEA region, during the month of APR the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 370.
In the EMEA region, during the month of APR the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 235.
In the EMEA region, during the month of APR the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 210.
In the EMEA region, during the month of APR the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 161.
In the EMEA region, during the month of APR the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 9076.
In the EMEA region, during the month of APR the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 700.
In the EMEA region, during the month of APR the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3393.
In the EMEA region, during the month of APR the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3374.
In the EMEA region, during the month of APR the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2452.
In the EMEA region, during the month of APR the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2252.
In the EMEA region, during the month of APR the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 1982.
In the EMEA region, during the month of APR the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1690.
In the EMEA region, during the month of APR the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1511.
In the EMEA region, during the month of APR the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1784.
In the EMEA region, during the month of APR the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 570.
In the EMEA region, during the month of APR the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 733.
In the North America region, during the month of APR the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 3483.
In the North America region, during the month of APR the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 3266.
In the North America region, during the month of APR the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2541.
In the North America region, during the month of APR the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 2284.
In the North America region, during the month of APR the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 2092.
In the North America region, during the month of APR the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1345.
In the North America region, during the month of APR the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 9756.
In the North America region, during the month of APR the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 9702.
In the North America region, during the month of APR the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 9116.
In the North America region, during the month of APR the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6620.
In the North America region, during the month of APR the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6783.
In the North America region, during the month of APR the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6922.
In the North America region, during the month of APR the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1546.
In the North America region, during the month of APR the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1521.
In the North America region, during the month of APR the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1543.
In the North America region, during the month of APR the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 421.
In the North America region, during the month of APR the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 404.
In the North America region, during the month of APR the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 431.
In the North America region, during the month of APR the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 644.
In the North America region, during the month of APR the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 757.
In the North America region, during the month of APR the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 599.
In the North America region, during the month of APR the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 2061.
In the North America region, during the month of APR the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 1739.
In the North America region, during the month of APR the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 1177.
In the North America region, during the month of APR the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 568.
In the North America region, during the month of APR the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 404.
In the North America region, during the month of APR the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 418.
In the North America region, during the month of APR the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 481.
In the North America region, during the month of APR the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 887.
In the North America region, during the month of APR the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 752.
In the North America region, during the month of APR the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 617.
In the North America region, during the month of APR the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 482.
In the North America region, during the month of APR the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 457.
In the North America region, during the month of APR the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 408.
In the North America region, during the month of APR the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 9323.
In the North America region, during the month of APR the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 947.
In the North America region, during the month of APR the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3640.
In the North America region, during the month of APR the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3621.
In the North America region, during the month of APR the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2699.
In the North America region, during the month of APR the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2499.
In the North America region, during the month of APR the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 2229.
In the North America region, during the month of APR the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1937.
In the North America region, during the month of APR the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1758.
In the North America region, during the month of APR the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 2031.
In the North America region, during the month of APR the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 817.
In the North America region, during the month of APR the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 980.
In the APAC region, during the month of MAY the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 2497.
In the APAC region, during the month of MAY the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 2706.
In the APAC region, during the month of MAY the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2544.
In the APAC region, during the month of MAY the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 1412.
In the APAC region, during the month of MAY the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 1656.
In the APAC region, during the month of MAY the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1540.
In the APAC region, during the month of MAY the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 8916.
In the APAC region, during the month of MAY the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 9444.
In the APAC region, during the month of MAY the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 9007.
In the APAC region, during the month of MAY the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6419.
In the APAC region, during the month of MAY the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6738.
In the APAC region, during the month of MAY the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6463.
In the APAC region, during the month of MAY the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1085.
In the APAC region, during the month of MAY the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1050.
In the APAC region, during the month of MAY the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1004.
In the APAC region, during the month of MAY the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 54.
In the APAC region, during the month of MAY the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 90.
In the APAC region, during the month of MAY the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 62.
In the APAC region, during the month of MAY the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 427.
In the APAC region, during the month of MAY the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 403.
In the APAC region, during the month of MAY the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 400.
In the APAC region, during the month of MAY the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 1089.
In the APAC region, during the month of MAY the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 1343.
In the APAC region, during the month of MAY the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 1202.
In the APAC region, during the month of MAY the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 279.
In the APAC region, during the month of MAY the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 57.
In the APAC region, during the month of MAY the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 70.
In the APAC region, during the month of MAY the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 130.
In the APAC region, during the month of MAY the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 510.
In the APAC region, during the month of MAY the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 383.
In the APAC region, during the month of MAY the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 255.
In the APAC region, during the month of MAY the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 128.
In the APAC region, during the month of MAY the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 89.
In the APAC region, during the month of MAY the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 37.
In the APAC region, during the month of MAY the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 9876.
In the APAC region, during the month of MAY the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 543.
In the APAC region, during the month of MAY the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3121.
In the APAC region, during the month of MAY the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3305.
In the APAC region, during the month of MAY the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2229.
In the APAC region, during the month of MAY the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2172.
In the APAC region, during the month of MAY the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 1783.
In the APAC region, during the month of MAY the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1505.
In the APAC region, during the month of MAY the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1337.
In the APAC region, during the month of MAY the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1700.
In the APAC region, during the month of MAY the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 445.
In the APAC region, during the month of MAY the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 661.
In the EMEA region, during the month of MAY the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 2597.
In the EMEA region, during the month of MAY the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 2806.
In the EMEA region, during the month of MAY the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2644.
In the EMEA region, during the month of MAY the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 1512.
In the EMEA region, during the month of MAY the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 1756.
In the EMEA region, during the month of MAY the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1640.
In the EMEA region, during the month of MAY the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 9016.
In the EMEA region, during the month of MAY the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 9544.
In the EMEA region, during the month of MAY the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 9107.
In the EMEA region, during the month of MAY the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6519.
In the EMEA region, during the month of MAY the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6838.
In the EMEA region, during the month of MAY the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6563.
In the EMEA region, during the month of MAY the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1185.
In the EMEA region, during the month of MAY the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1150.
In the EMEA region, during the month of MAY the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1104.
In the EMEA region, during the month of MAY the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 154.
In the EMEA region, during the month of MAY the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 190.
In the EMEA region, during the month of MAY the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 162.
In the EMEA region, during the month of MAY the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 527.
In the EMEA region, during the month of MAY the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 503.
In the EMEA region, during the month of MAY the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 500.
In the EMEA region, during the month of MAY the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 1189.
In the EMEA region, during the month of MAY the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 1443.
In the EMEA region, during the month of MAY the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 1302.
In the EMEA region, during the month of MAY the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 379.
In the EMEA region, during the month of MAY the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 157.
In the EMEA region, during the month of MAY the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 170.
In the EMEA region, during the month of MAY the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 230.
In the EMEA region, during the month of MAY the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 610.
In the EMEA region, during the month of MAY the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 483.
In the EMEA region, during the month of MAY the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 355.
In the EMEA region, during the month of MAY the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 228.
In the EMEA region, during the month of MAY the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 189.
In the EMEA region, during the month of MAY the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 137.
In the EMEA region, during the month of MAY the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 9976.
In the EMEA region, during the month of MAY the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 643.
In the EMEA region, during the month of MAY the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3221.
In the EMEA region, during the month of MAY the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3405.
In the EMEA region, during the month of MAY the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2329.
In the EMEA region, during the month of MAY the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2272.
In the EMEA region, during the month of MAY the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 1883.
In the EMEA region, during the month of MAY the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1605.
In the EMEA region, during the month of MAY the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1437.
In the EMEA region, during the month of MAY the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1800.
In the EMEA region, during the month of MAY the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 545.
In the EMEA region, during the month of MAY the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 761.
In the North America region, during the month of MAY the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 2844.
In the North America region, during the month of MAY the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 3053.
In the North America region, during the month of MAY the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2891.
In the North America region, during the month of MAY the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 1759.
In the North America region, during the month of MAY the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 2003.
In the North America region, during the month of MAY the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1887.
In the North America region, during the month of MAY the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 9263.
In the North America region, during the month of MAY the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 9791.
In the North America region, during the month of MAY the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 9354.
In the North America region, during the month of MAY the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6766.
In the North America region, during the month of MAY the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 7085.
In the North America region, during the month of MAY the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6810.
In the North America region, during the month of MAY the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1432.
In the North America region, during the month of MAY the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1397.
In the North America region, during the month of MAY the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1351.
In the North America region, during the month of MAY the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 401.
In the North America region, during the month of MAY the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 437.
In the North America region, during the month of MAY the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 409.
In the North America region, during the month of MAY the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 774.
In the North America region, during the month of MAY the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 750.
In the North America region, during the month of MAY the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 747.
In the North America region, during the month of MAY the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 1436.
In the North America region, during the month of MAY the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 1690.
In the North America region, during the month of MAY the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 1549.
In the North America region, during the month of MAY the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 626.
In the North America region, during the month of MAY the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 404.
In the North America region, during the month of MAY the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 417.
In the North America region, during the month of MAY the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 477.
In the North America region, during the month of MAY the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 857.
In the North America region, during the month of MAY the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 730.
In the North America region, during the month of MAY the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 602.
In the North America region, during the month of MAY the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 475.
In the North America region, during the month of MAY the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 436.
In the North America region, during the month of MAY the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 384.
In the North America region, during the month of MAY the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 10223.
In the North America region, during the month of MAY the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 890.
In the North America region, during the month of MAY the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3468.
In the North America region, during the month of MAY the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3652.
In the North America region, during the month of MAY the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2576.
In the North America region, during the month of MAY the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2519.
In the North America region, during the month of MAY the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 2130.
In the North America region, during the month of MAY the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1852.
In the North America region, during the month of MAY the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1684.
In the North America region, during the month of MAY the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 2047.
In the North America region, during the month of MAY the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 792.
In the North America region, during the month of MAY the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 1008.
In the APAC region, during the month of JUN the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 2561.
In the APAC region, during the month of JUN the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 1698.
In the APAC region, during the month of JUN the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2719.
In the APAC region, during the month of JUN the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 1383.
In the APAC region, during the month of JUN the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 633.
In the APAC region, during the month of JUN the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1536.
In the APAC region, during the month of JUN the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 9389.
In the APAC region, during the month of JUN the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 8506.
In the APAC region, during the month of JUN the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 9071.
In the APAC region, during the month of JUN the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6828.
In the APAC region, during the month of JUN the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6808.
In the APAC region, during the month of JUN the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6352.
In the APAC region, during the month of JUN the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1178.
In the APAC region, during the month of JUN the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1065.
In the APAC region, during the month of JUN the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1183.
In the APAC region, during the month of JUN the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 65.
In the APAC region, during the month of JUN the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 87.
In the APAC region, during the month of JUN the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 52.
In the APAC region, during the month of JUN the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 370.
In the APAC region, during the month of JUN the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 529.
In the APAC region, during the month of JUN the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 419.
In the APAC region, during the month of JUN the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 1079.
In the APAC region, during the month of JUN the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 191.
In the APAC region, during the month of JUN the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 1169.
In the APAC region, during the month of JUN the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 132.
In the APAC region, during the month of JUN the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 56.
In the APAC region, during the month of JUN the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 70.
In the APAC region, during the month of JUN the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 125.
In the APAC region, during the month of JUN the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 540.
In the APAC region, during the month of JUN the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 405.
In the APAC region, during the month of JUN the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 270.
In the APAC region, during the month of JUN the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 135.
In the APAC region, during the month of JUN the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 93.
In the APAC region, during the month of JUN the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 64.
In the APAC region, during the month of JUN the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 8765.
In the APAC region, during the month of JUN the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 589.
In the APAC region, during the month of JUN the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3285.
In the APAC region, during the month of JUN the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 2977.
In the APAC region, during the month of JUN the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2347.
In the APAC region, during the month of JUN the CRG - Clinical group operating under the Development division, achieved a Target Sales of 1956.
In the APAC region, during the month of JUN the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 1873.
In the APAC region, during the month of JUN the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1445.
In the APAC region, during the month of JUN the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1405.
In the APAC region, during the month of JUN the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1531.
In the APAC region, during the month of JUN the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 469.
In the APAC region, during the month of JUN the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 395.
In the EMEA region, during the month of JUN the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 2661.
In the EMEA region, during the month of JUN the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 1798.
In the EMEA region, during the month of JUN the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 2819.
In the EMEA region, during the month of JUN the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 1483.
In the EMEA region, during the month of JUN the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 733.
In the EMEA region, during the month of JUN the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1636.
In the EMEA region, during the month of JUN the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 9489.
In the EMEA region, during the month of JUN the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 8606.
In the EMEA region, during the month of JUN the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 9171.
In the EMEA region, during the month of JUN the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 6928.
In the EMEA region, during the month of JUN the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 6908.
In the EMEA region, during the month of JUN the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6452.
In the EMEA region, during the month of JUN the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1278.
In the EMEA region, during the month of JUN the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1165.
In the EMEA region, during the month of JUN the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1283.
In the EMEA region, during the month of JUN the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 165.
In the EMEA region, during the month of JUN the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 187.
In the EMEA region, during the month of JUN the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 152.
In the EMEA region, during the month of JUN the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 470.
In the EMEA region, during the month of JUN the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 629.
In the EMEA region, during the month of JUN the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 519.
In the EMEA region, during the month of JUN the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 1179.
In the EMEA region, during the month of JUN the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 291.
In the EMEA region, during the month of JUN the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 1269.
In the EMEA region, during the month of JUN the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 232.
In the EMEA region, during the month of JUN the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 156.
In the EMEA region, during the month of JUN the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 170.
In the EMEA region, during the month of JUN the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 225.
In the EMEA region, during the month of JUN the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 640.
In the EMEA region, during the month of JUN the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 505.
In the EMEA region, during the month of JUN the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 370.
In the EMEA region, during the month of JUN the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 235.
In the EMEA region, during the month of JUN the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 193.
In the EMEA region, during the month of JUN the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 164.
In the EMEA region, during the month of JUN the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 8865.
In the EMEA region, during the month of JUN the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 689.
In the EMEA region, during the month of JUN the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3385.
In the EMEA region, during the month of JUN the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3077.
In the EMEA region, during the month of JUN the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2447.
In the EMEA region, during the month of JUN the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2056.
In the EMEA region, during the month of JUN the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 1973.
In the EMEA region, during the month of JUN the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1545.
In the EMEA region, during the month of JUN the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1505.
In the EMEA region, during the month of JUN the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1631.
In the EMEA region, during the month of JUN the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 569.
In the EMEA region, during the month of JUN the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 495.
In the North America region, during the month of JUN the AIG - Analytical group operating under the Chromatography division, achieved a Actual Gross Profit of 2908.
In the North America region, during the month of JUN the AIG - Analytical group operating under the Chromatography division, achieved a Target Gross Profit of 2045.
In the North America region, during the month of JUN the AIG - Analytical group operating under the Chromatography division, achieved a Last Year Gross Profit of 3066.
In the North America region, during the month of JUN the AIG - Analytical group operating under the Analysis Division division, achieved a Actual Operating Profit(EBIT) of 1730.
In the North America region, during the month of JUN the AIG - Analytical group operating under the Analysis Division division, achieved a Target Operating Profit(EBIT) of 980.
In the North America region, during the month of JUN the AIG - Analytical group operating under the Analysis Division division, achieved a Last Year Operating Profit(EBIT) of 1883.
In the North America region, during the month of JUN the CRG - Clinical group operating under the Development division, achieved a Actual Total Revenue of 9736.
In the North America region, during the month of JUN the CRG - Clinical group operating under the Development division, achieved a Target Total Revenue of 8853.
In the North America region, during the month of JUN the CRG - Clinical group operating under the Development division, achieved a Last Year Total Revenue of 9418.
In the North America region, during the month of JUN the GSG - Genetic group operating under the next-gen division, achieved a Actual Cost Of Goods Sold of 7175.
In the North America region, during the month of JUN the GSG - Genetic group operating under the next-gen division, achieved a Target Cost Of Goods Sold of 7155.
In the North America region, during the month of JUN the GSG - Genetic group operating under the next-gen division, achieved a Last Year Cost Of Goods Sold of 6699.
In the North America region, during the month of JUN the GSG - Genetic group operating under the Solutions division, achieved a Actual Total Operating Expense of 1525.
In the North America region, during the month of JUN the GSG - Genetic group operating under the Solutions division, achieved a Target Total Operating Expense of 1412.
In the North America region, during the month of JUN the GSG - Genetic group operating under the Solutions division, achieved a Last Year Total Operating Expense of 1530.
In the North America region, during the month of JUN the BPG  group operating under the Gene Therapy division, achieved a Actual Other Non Operatng Income/Expense of 412.
In the North America region, during the month of JUN the BPG  group operating under the Gene Therapy division, achieved a Target Other Non Operatng Income/Expense of 434.
In the North America region, during the month of JUN the BPG  group operating under the Gene Therapy division, achieved a Last Year Other Non Operatng Income/Expense of 399.
In the North America region, during the month of JUN the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Finance Expense of 717.
In the North America region, during the month of JUN the SDG - Specialty group operating under the Diagnostics division, achieved a Target Finance Expense of 876.
In the North America region, during the month of JUN the SDG - Specialty group operating under the Diagnostics division, achieved a Last Year Finance Expense of 766.
In the North America region, during the month of JUN the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Profit Before Tax of 1426.
In the North America region, during the month of JUN the SDG - Specialty group operating under the Market Division division, achieved a Target Net Profit Before Tax of 538.
In the North America region, during the month of JUN the SDG - Specialty group operating under the Market Division division, achieved a Last Year Net Profit Before Tax of 1516.
In the North America region, during the month of JUN the SDG - Specialty group operating under the Market Division division, achieved a Actual Net Operating Cashflow of 479.
In the North America region, during the month of JUN the LSLPG - Life group operating under the Sciences and Lab division, achieved a Male HeadCount of 403.
In the North America region, during the month of JUN the LSLPG - Life group operating under the Sciences and Lab division, achieved a Female HeadCount of 417.
In the North America region, during the month of JUN the LSLPG - Life group operating under the Sciences and Lab division, achieved a Last Year HeadCount of 472.
In the North America region, during the month of JUN the CRG - Clinical group operating under the Development division, achieved a <30days Receivable Ageing of 887.
In the North America region, during the month of JUN the CRG - Clinical group operating under the Development division, achieved a <60days Receivable Ageing of 752.
In the North America region, during the month of JUN the LSLPG - Life group operating under the BioProduction division, achieved a <90days Receivable Ageing of 617.
In the North America region, during the month of JUN the LSLPG - Life group operating under the BioProduction division, achieved a >90days Receivable Ageing of 482.
In the North America region, during the month of JUN the PSG - Pharma group operating under the Trials Division division, achieved a Actual Days Receivable Outstanding of 440.
In the North America region, during the month of JUN the PSG - Pharma group operating under the Product Division division, achieved a Actual Days Inventory outstanding of 411.
In the North America region, during the month of JUN the PSG - Pharma group operating under the Product Division division, achieved a Actual Inventory of 9112.
In the North America region, during the month of JUN the PSG - Pharma group operating under the Product Division division, achieved a Actual Employee Cost of 936.
In the North America region, during the month of JUN the AIG - Analytical group operating under the Chromatography division, achieved a Actual Sales of 3632.
In the North America region, during the month of JUN the AIG - Analytical group operating under the Chromatography division, achieved a Target Sales of 3324.
In the North America region, during the month of JUN the CRG - Clinical group operating under the Development division, achieved a Actual Sales of 2694.
In the North America region, during the month of JUN the CRG - Clinical group operating under the Development division, achieved a Target Sales of 2303.
In the North America region, during the month of JUN the GSG - Genetic group operating under the next-gen division, achieved a Actual Sales of 2220.
In the North America region, during the month of JUN the GSG - Genetic group operating under the next-gen division, achieved a Target Sales of 1792.
In the North America region, during the month of JUN the SDG - Specialty group operating under the Diagnostics division, achieved a Actual Sales of 1752.
In the North America region, during the month of JUN the SDG - Specialty group operating under the Diagnostics division, achieved a Target Sales of 1878.
In the North America region, during the month of JUN the PSG - Pharma group operating under the Trials Division division, achieved a Actual Sales of 816.
In the North America region, during the month of JUN the PSG - Pharma group operating under the Trials Division division, achieved a Target Sales of 742.
